Sara Dubois1†
Francesca Marchese2†
Federica Pigliasco3Sebastiano Barco3Gino Tripodi3
Tommaso Lomonaco4
Simona Lattanzi5
Emilio Russo6Giuliana Cangemi3
Pasquale Striano1,2*- 1Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy
- 2Pediatric Neurology and Muscular Diseases Unit, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 3Chromatography and Mass Spectrometry Section, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genoa, Italy
- 4Department of Chemistry and Industrial Chemistry, University of Pisa, Pisa, Italy
- 5Neurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Ancona, Italy
- 6Science of Health Department, School of Medicine, University Magna Graecia, Catanzaro, Italy
Purpose: Interest in cannabis-based therapies has recently increased, due to the availability of cannabidiol (CBD) for the treatment of epilepsy without psychoactive effects. Therapeutic drug monitoring can prevent drug interactions and minimize drug toxicity. We evaluated a volumetric absorptive microsampling (VAMS) method combined with LC-MS/MS (liquid chromatography coupled to tandem mass spectrometry) for the quantification of CBD blood levels in patients with refractory epilepsy.
Methods: Prospective observation of patients with Dravet syndrome receiving open-label, add-on GW-purified CBD (Epidyolex®) at different doses. CBD plasma samples were obtained from venipuncture and LC-MS/MS was used to measure CBD in venous and capillary blood samples collected by VAMS.
Results: We enrolled five patients with a mean age of 13 (range: 4–27) years. CBD levels measured by VAMS on capillary blood did not differ from CBD levels measured in plasma by venipuncture (R2 > 0.93).
Conclusion: This proof-of-concept study suggests that VAMS allows monitoring of CBD plasma levels and can offer valuable support for personalized therapy in refractory epilepsy.
Introduction
Epilepsy is one of the most common brain chronic disorders, affecting around 70 million people of all ages worldwide (Hirtz et al., 2007; Zaccara and Schmidt, 2017). The identification of the appropriate treatment allows in most patients a medium and long-term remission in seizures control (Striano and Striano, 2009; Striano et al., 2016; Lattanzi et al., 2019). Despite the use of numerous therapeutic options, including third-generation antiseizure medications (ASMs), neuromodulation, surgical and dietary interventions, 30% of patients continue to have seizures (Striano and Striano, 2009; Zaccara and Schmidt, 2017).
The interest in cannabis-based therapies has increased, in particular in the two main phytocannabinoids: cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC). CBD stimulates interest because of its anti-convulsive properties in absence of psychoactive effects and abuse liability, unlike THC (Devinsky et al., 2014; Arzimanoglou et al., 2020). The therapeutic potential of galenic preparations marketed to contain CBD/THC was found to depend on preparation procedures, components concentration, and presence of other constituents (De Caro et al., 2017; Carcieri et al., 2018; Lattanzi et al., 2018; Lattanzi et al., 2019). Purified CBD produced by GW pharma (EPIDYOLEX®) is the first of a new class of ASMs. (Lattanzi et al., 2019; Lattanzi et al., 2020). The approval in July 2019 by the European Medicines Agency to use CBD as an additional treatment with clobazam in two forms of childhood refractory epilepsy (Dravet syndrome and Lennox-Gastaut syndrome) is a milestone in the medical use of phytocannabinoids for the treatment of epileptic disorders. Due to the heterogeneity of epilepsy clinical manifestations and interindividual response to old and new antiepileptic drugs, therapeutic drug monitoring (TDM) is a valuable clinical support in patients’ treatment.
In refractory epilepsy, the relationship between the dose administered and CBD blood levels demonstrated in some studies (Geffrey et al., 2015; Landmark and Brandl, 2020) has provided a starting point for the use of TDM in the wide variability of CBD pharmacokinetics (Ocque et al., 2019). TDM is useful in clinical practice as it allows to obtain the ideal dose of cannabis-based therapy based on the identification of the individual concentration associated with an optimal response. Moreover, in polypharmacy TDM can prevent drug interactions by guiding dose adjustments and minimizing toxicity (Striano et al., 2008; Patsalos et al., 2018; Brandt, 2019). Microsampling techniques based on dried blood spots allow a reliable and non-invasive collection of small blood volumes. Recently, the novel device VAMS (Volumetric Absorptive Microsampling) has been introduced in the market, commercial name MITRA®, successfully applied to several quantitative TDM methods. This device allows the collection of a fixed volume of blood (10 or 30 µl) avoiding the effect of hematocrit (HCT) on the analytical performances (Mano et al., 2015; Barco et al., 2017; Kok and Fillet, 2018; DʼUrso et al., 2019). We evaluated VAMS in combination with liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) for the quantification of CBD blood levels to be used in clinical practice to personalize the cannabis-based treatment of refractory epilepsy. In particular, we determined CBD concentrations in capillary and venous blood obtained by micro-sampling and compared them with CBD concentration in plasma, which is the matrix most frequently used for TDM in epilepsy patients.
Methods
Participants
We investigated five subjects with Dravet syndrome treated with CBD oral solution (Epidyolex®) given for compassionate use. All participants were taking a stable dose of ASMs and were followed-up prospectively through medical charts and parents/caregivers’ information.
Study Design
Patients received Epidyolex as compassionate use approved by the Regional Ethics Committee. Written informed consent was signed by parents, caregivers, or legal representatives. CBD was administered at the initial dose of 2.5 mg/kg two times per day (5 mg/kg/day) to be increased after 1 week to a maintenance dosage of 5 mg/kg twice daily (10 mg/kg/day). The CBD dose could be increased in weekly increments of 2.5 mg/kg twice daily according to clinical response. Physical examination and laboratory tests (FBC, serum sodium, potassium, chloride, creatinine, ALT, AST, total bilirubin, INR, and glucose) were performed at baseline (within 2 weeks after initiation of CBD treatment) and after 1 month, 3 months, and 6 months of treatment. Patients’ parameters, i.e., weight, height, and body mass index, were recorded at each scheduled visit and a safety check was carried out by monitoring CBD plasma levels by venipuncture. CBD blood levels were evaluated at least 3 months after the start of treatment. During the monitoring study of the different cannabis-based therapies, the doses of concomitant ASMs administered to patients were not modified, establishing an appropriate observation condition.
Quantification of Cannabidiol in Plasma by Volumetric Absorptive Microsampling-Liquid Chromatography Coupled to Tandem Mass Spectrometry
Blood samples were obtained in the morning before the first daily medication. Venous blood was collected by venipuncture on tubes containing ethylenediaminetetraacetic acid and plasma was separated by centrifugation at 2,000 g for 5 min. The 30 µl VAMS devices (MITRA®, Neoteryx, Torrance, CA, United States) were used to collect venous and capillary blood. The venous VAMS samples were obtained from blood collected by ethylenediaminetetraacetic acid tubes, as described (Barco et al., 2018; Pigliasco et al., 2020). Capillary VAMS were obtained following the manufacturer’s instructions: before pricking the patient’s finger with a microneedle, the area was disinfected and after the first drop of blood was removed, the VAMS tip was placed in contact with the surface of the second drop to adsorb the matrix.
Statistical Analysis
The correlation between CBD venous and capillary VAMS and CBD plasma levels was assessed by linear regression analysis (“Medcalc,” Software Ltd., Ostend, Belgium).
Results
Demographic Characteristics and Compliance
The demographic and clinical features of the participants are summarized in Table 1. Four subjects were males and the mean age of the five patients was 13 (range: 4–27) years. At enrollment, all participants had failed from two to four ASMs and were on stable treatment (mean: three concomitant drugs) for at least 3 months before CBD add-on. Table 1 also shows the dose and amount of CBD provided to each subject. The mean dose of Epidyolex administered was 658 mg/day (15 mg/kg/day).
TABLE 1. Demographic and clinical features of the patients.
Outcome Therapeutic Monitoring Cannabidiol Levels by Venipuncture and Volumetric Absorptive Microsampling
The results achieved from the analysis of plasma and venous and capillary VAMS are illustrated in Table 2. The highest CBD plasma levels, ranging from 356 to 64 ng/ml (mean CBD level 175 ± 102 ng/ml), were related to Epidyolex administered at a mean dosage of 15 mg/kg/day. Linear regression analysis (Figure 1) showed a correlation between CBD concentrations measured on capillary blood sampled by VAMS did not differ from those measured by venous VAMS (R2 > 0.98) and plasma from venipuncture (R2 > 0.93).
TABLE 2. CBD therapeutic monitoring by VAMS and venipuncture including formulation and dose cannabis-based treatment.
FIGURE 1. Linear regression analysis showing the correlation between cannabidiol plasma levels from venipuncture and cannabidiol concentrations measured by venous and capillary volumetric absorptive microsampling (VAMS).
Discussion
TDM is often indispensable in the follow-up of epilepsy patients for the need of dose adjustments to optimize the clinical outcome (Kok and Fillet, 2018; Patsalos et al., 2018). VAMS devices are porous hydrophilic tips that enable an accurate collection of small blood volumes (Denniff and Spooner, 2014) avoiding the volumetric HCT bias and erythrocyte volume fraction bias associated with the non-volumetric dried blood spots approach (De Kesel et al., 2014; Denniff and Spooner, 2014; Spooner et al., 2015). Moreover, a significant advantage of this less invasive and easily reproducible procedure is that it limits the discomfort caused to patients in obtaining venous samples. However, to date, the TDM of medical cannabis has few validated analytical methods on plasma (Grauwiler et al., 2007; Aizpurua-Olaizola et al., 2017; Lomonaco et al., 2018; Pigliasco et al., 2020).
We used a new microsampling method for the determination of CBD blood levels in patients with drug-resistant epilepsy using VAMS, which had previously proven useful for quantitative measurement of several venous and capillary blood drugs, including first and third-generation antiepileptic drugs (Velghe and Stove, 2018; DʼUrso et al., 2019), antibiotics (Barco et al., 2017) and immunosuppressants (Koster et al., 2019).
Specifically, we aimed to evaluate the correspondence between the CBD levels detected in plasma and those measured using the VAMS technique, by pricking the patient’s finger. CBD concentrations that were taken from capillary blood by VAMS were not statistically different from those of venous blood obtained in the laboratory from the same device. Also, this statistical comparison proved to be valid between the results collected from VAMS microsampling and the CBD plasma levels obtained by venipuncture.
Several factors may influence the pharmacokinetics of CBD-related products used (Lucas et al., 2018; Birnbaum et al., 2019). In particular, CBD is related to a high potential of drug-drug interactions due to the influence on the activity of several enzymes involved in the metabolism of antiseizure medications, including cytochromes CYP2C and CYP3A, isoenzymes of CYP450. The known increase in plasma levels of N-desmethylclobazam (N-CLB), an active metabolite of clobazam, due to inhibition of the catalytic activity of CYP2C19 by CBD, is responsible for the most common dose-dependent adverse event in the clinical practice (Lattanzi et al., 2020) In this study, we did not methodically collect the plasma N-CLB levels in our patients treated with clobazam. Moreover, our study was not designed to monitor high intra- and inter-individual pharmacokinetic variability, although the implementation of the patient cohort could provide additional investigation material.
Conclusion
VAMS device can be used as valuable support for patients with refractory epilepsy allowing control of CBD concentrations and dosage regulation, minimizing interindividual pharmacokinetic and pharmacodynamic problems, obtaining an effective personalized treatment and better control of therapeutic adherence. Our findings should be confirmed in further follow-up studies on larger series to identify a standardized match between the administered CBD dose and its detectable plasma concentration.
Data Availability Statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
The studies involving human participants were reviewed and approved by CER Liguria. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.
Author Contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of Interest
PS received advisory board fees from GW pharma and research grants from GW pharma and Enecta.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was developed within the framework of the DINOGMI Department of Excellence of MIUR 2018–2022 (legge 232 del 2016). We thank Prof. Carlo Minetti for his help in publishing this paper.
References
Aizpurua-Olaizola, O., Zarandona, I., Ortiz, L., Navarro, P., Etxebarria, N., and Usobiaga, A. (2017). Simultaneous quantification of major cannabinoids and metabolites in human urine and plasma by HPLC-MS/MS and enzyme-alkaline hydrolysis. Drug Test. Anal. 9 (4), 626–633. doi:10.1002/dta.1998
Arzimanoglou, A., Brandl, U., Cross, J. H., Gil-Nagel, A., Lagae, L., Landmark, C. J., et al. ; The Cannabinoids International Experts Panel, Collaborators (2020). Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord. 22, 1–14. doi:10.1684/epd.2020.1141
Barco, S., Castagnola, E., Moscatelli, A., Rudge, J., Tripodi, G., and Cangemi, G. (2017). Volumetric adsorptive microsampling-liquid chromatography tandem mass spectrometry assay for the simultaneous quantification of four antibiotics in human blood: method development, validation and comparison with dried blood spot. J. Pharmaceut. Biomed. Anal. 145, 704–710. doi:10.1016/j.jpba.2017.07.033
Barco, S., Fucile, C., Manfredini, L., Grandis, E. D., Gherzi, M., Martelli, A., et al. (2018). A UHPLC-MS/MS method for the quantification of Δ9-tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis. Bioanalysis 10 (24), 2003–2014. doi:10.4155/bio-2018-0184
Birnbaum, A. K., Karanam, A., Marino, S. E., Barkley, C. M., Remmel, R. P., Roslawski, M., et al. (2019). Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy. Epilepsia 60, 1586–1592. doi:10.1111/epi.16093
Brandt, C. (2019). Pharmacodynamic monitoring of antiepileptic drug therapy. Ther. Drug Monit. 41 (2), 168–173. doi:10.1097/ftd.0000000000000623
Carcieri, C., Tomasello, C., and Simiele, M. (2018). Cannabinoids concentration variability in cannabis olive oil galenic preparations. J. Pharm. Pharmacol. 70 (1), 143–149. doi:10.1111/jphp.12845
De Caro, C., Leo, A., Citraro, R., De Sarro, C., Russo, R., Calignano, A., et al. (2017). The potential role of cannabinoids in epilepsy treatment. Expert Rev. Neurother. 17 (11), 1069–1079. doi:10.1080/14737175.2017.1373019
De Kesel, P. M., Capiau, S., Lambert, W. E., and Stove, C. P. (2014). Current strategies for coping with the hematocrit problem in dried blood spot analysis. Bioanalysis 6 (14), 1871–1874. doi:10.4155/bio.14.151
Denniff, P., and Spooner, N. (2014). Volumetric absorptive microsampling: a dried sample collection technique for quantitative bioanalysis. Anal. Chem. 86 (16), 8489–8495. doi:10.1021/ac5022562
Devinsky, O., Cilio, M. R., Cross, H., Fernandez-Ruiz, J., French, J., Hill, C., et al. (2014). Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia 55 (6), 791–802. doi:10.1111/epi.12631
DʼUrso, A., Rudge, J., Patsalos, P. N., and de Grazia, U. (2019). Volumetric absorptive microsampling: a new sampling tool for therapeutic drug monitoring of antiepileptic drugs. Ther. Drug Monit. 41 (5), 681–692. doi:10.1097/FTD.0000000000000652
Geffrey, A. L., Pollack, S. F., Bruno, P. L., and Thiele, E. A. (2015). Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 56 (8), 1246–1251. doi:10.1111/epi.13060
Grauwiler, S. B., Scholer, A., and Drewe, J. (2007). Development of a LC/MS/MS method for the analysis of cannabinoids in human EDTA-plasma and urine after small doses of Cannabis sativa extracts. J. Chromatogr. B 850 (1–2), 515–522. doi:10.1016/j.jchromb.2006.12.045
Hirtz, D., Thurman, D. J., Gwinn-Hardy, K., Mohamed, M., Chaudhuri, A. R., and Zalutsky, R. (2007). How common are the “common” neurologic disorders? Neurology 68 (5), 326–337. doi:10.1212/01.wnl.0000252807.38124.a3
Kok, M. G. M., and Fillet, M. (2018). Volumetric absorptive microsampling: current advances and applications. J. Pharmaceut. Biomed. Anal. 147, 288–296. doi:10.1016/j.jpba.2017.07.029
Koster, R. A., Niemeijer, P., Veenhof, H., Hateren, K. v., Alffenaar, J.-W. C., Touw, D. J., et al. (2019). A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects. Bioanalysis 11 (6), 495–508. doi:10.4155/bio-2018-0312
Landmark, C. J., and Brandl, U. (2020). Pharmacology and drug interactions of cannabinoids. Epileptic Disord. 22 (S1), 16–22. doi:10.1684/epd.2019.1123
Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Cagnetti, C., Del Giovane, C., et al. (2018). Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis. Drugs 78 (17), 1791–1804. doi:10.1007/s40265-018-0992-5
Lattanzi, S., Brigo, F., Trinka, E., Zaccara, G., Striano, P., Del Giovane, C., et al. (2020). Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs 34 (3), 229–241. doi:10.1007/s40263-020-00708-6
Lattanzi, S., Trinka, E., Russo, E., Striano, P., Citraro, R., Silvestrini, M., et al. (2019). Cannabidiol as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. Drugs Today 55 (3), 177–196. doi:10.1358/dot.2019.55.3.2909248
Lattanzi, S., Trinka, E., Striano, P., Zaccara, G., Del Giovane, C., Nardone, R., et al. (2020). Cannabidiol efficacy and clobazam status: a systematic review and meta-analysis. Epilepsia, 1–9. doi:10.1111/epi.16546
Lattanzi, S., Zaccara, G., Giovannelli, F., Grillo, E., Nardone, R., Silvestrini, M., et al. (2019). Antiepileptic monotherapy in newly diagnosed focal epilepsy. A network meta-analysis. Acta Neurol. Scand. 139 (1), 33–41. doi:10.1111/ane.13025
Lomonaco, T., Ghimenti, S., Piga, I., Biagini, D., Onor, M., Fuoco, R., et al. (2018). Monitoring of warfarin therapy: preliminary results from a longitudinal pilot study. Microchem. J. 13, 170–176. doi:10.1016/j.microc.2017.02.010
Lucas, C. J., Galettis, P., and Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. Br. J. Clin. Pharmacol. 84, 2477–2482. doi:10.1111/bcp.13710
Mano, Y., Kita, K., and Kusano, K. (2015). Hematocrit-independent recovery is a key for bioanalysis using volumetric absorptive microsampling devices, MitraTM. Bioanalysis 7 (15), 1821–1829. doi:10.4155/bio.15.111
Ocque, A. J., Hagler, C. E., DiFrancesco, R., Lombardo, J., and Morse, G. D. (2019). Development and validation of an assay to measure cannabidiol and Δ9-tetrahydrocannabinol in human EDTA plasma by UHPLC-MS/MS. J. Chromatogr. B 1112, 56–60. doi:10.1016/j.jchromb.2019.03.002
Patsalos, P. N., Spencer, E. P., and Berry, D. J. (2018). Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther. Drug Monit. 40 (5), 526–548. doi:10.1097/FTD.0000000000000546
Pigliasco, F., Barco, S., Dubois, S., Marchese, F., Striano, P., Lomonaco, T., et al. (2020). Cannabidiol determination on peripheral capillary blood using a microsampling method and ultra-high-performance liquid chromatography tandem mass spectrometry with on-line sample preparation. Molecules 25 (16), 3608. doi:10.3390/molecules25163608
Spooner, N., Denniff, P., Michielsen, L., De Vries, R., Ji, Q. C., Arnold, M. E., et al. (2015). A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit. Bioanalysis 7 (6), 653–659. doi:10.4155/bio.14.310.24
Striano, P., Belcastro, V., Coppola, A., Minetti, C., and Striano, S. (2016). Antiepileptic drugs under investigation for treatment of focal epilepsy. Clin. Neuropharmacol. 39 (6), 281–287. doi:10.1097/wnf.0000000000000180
Striano, P., and Striano, S. (2009). New and investigational antiepileptic drugs. Expet Opin. Invest. Drugs 18 (12), 1875–1884. doi:10.1517/13543780903369341
Striano, S., Striano, P., Capone, D., and Pisani, F. (2008). Limited place for plasma monitoring of new antiepileptic drugs in clinical practice. Med. Sci. Monit. 14 (10), RAI173-8. 18830207
Velghe, S., and Stove, C. P. (2018). Volumetric absorptive microsampling as an alternative tool for therapeutic drug monitoring of first-generation anti-epileptic drugs. Anal. Bioanal. Chem. 410 (9), 2331–2341. doi:10.1007/s00216-018-0866-4
Keywords: epilepsy, therapy, cannabidiol, therapeutic drug monitoring, volumetric absorptive microsampling, refractory seizures
Citation: Dubois S, Marchese F, Pigliasco F, Barco S, Tripodi G, Lomonaco T, Lattanzi S, Russo E, Cangemi G and Striano P (2020) A Volumetric Absorptive Microsampling Technique to Monitor Cannabidiol Levels in Epilepsy Patients. Front. Pharmacol. 11:582286. doi: 10.3389/fphar.2020.582286
Received: 11 July 2020; Accepted: 14 October 2020;
Published: 16 November 2020.
Edited by:
Gustavo Gonzalez-Cuevas, Idaho State University, United StatesReviewed by:
Guillermo Moreno-Sanz, Khiron Life Science Corp, SpainElizabeth Martina Bebin, University of Alabama at Birmingham, United States
Copyright © 2020 Dubois, Marchese, Pigliasco, Barco, Tripodi, Lomonaco, Lattanzi, Russo, Cangemi and Striano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence Pasquale Striano, strianop@gmail.com
†These authors have contributed equally to this work